You are here

Jesse Boehm

Publications

Berger AH, et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell. 2016 Aug 8;30(2):214-28.

Kim E, et al. Systematic functional interrogation of rare cancer variants identifies oncogenic allelesCancer Discov. 2016 Jul;6(7):714-26.

Hong AL, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 Jun 22;7:11987.

Boehm JS, Golub TR. An ecosystem of cancer cell line factories to support a cancer dependency map. Nat Rev Genet. 2015 Jul;16(7):373-4.

Jesse Boehm, Ph.D.

Jesse Boehm is the associate director of the Broad Institute’s Cancer Program, the director of the institute’s Cancer Cell Line Factory (CCLF) initiative, and a principal investigator in the Broad’s Cancer Model Development Center (part of the National Cancer Institute’s Human Cancer Models Initiative). Boehm is also a Merkin Institute Research Fellow.

In these roles, he works closely with Cancer Program director Todd Golub in the scientific planning and strategic execution of program projects, collaborations, and activities, with particular focus on senior strategic leadership of the Broad’s Dependency Map initiative, together with co-principle investigators Golub and institute member William Hahn.

In addition, Boehm leads a research laboratory focused on developing powerful methods and tools to accelerate the translation of cancer genomics into cancer therapeutics. Active projects include developing pipelines for personalized testing of tumor vulnerabilities as part of the CCLF, assessing the tumorigenic potential of thousands of new cancer mutations as part of the Cancer Program’s Target Accelerator initiative. The research group has an ultimate goal of making “precision functional genomics” a reality.

Previously, Boehm worked as a research scientist in the Broad Cancer Program. In this role he managed several large, collaborative research efforts that spanned multiple platforms, programs, and initiatives at the Broad Institute and the Dana-Farber Cancer Institute (DFCI). These included the generation of functional genomics tools for the community as well as the deployment of these tools in systematic, high-throughput experiments to determine the function of elements in the cancer genome.

Boehm received his B.S. in biology from MIT and his Ph.D. from Harvard University, Division of Medical Sciences. For his graduate studies, he worked in the Hahn laboratory at DFCI, where he developed and utilized new experimental models of cellular transformation, the process by which cells become cancerous.

January 2017